Sponsored

PhotosoftTM opens new avenues for Invion (ASX:IVX), shows antiviral activity against Zika virus - Kalkine Media

Follow us on Google News:
 Photosoft<sup>TM</sup> opens new avenues for Invion (ASX:IVX), shows antiviral activity against Zika virus
Image source: © Tanyapeliustka | Megapixl.com

Highlights

  • Invion has secured positive screening results from the in vitro study of PhotosoftTM technology against the Zika virus.
  • Currently, there is no treatment available for the Zika virus, and its market is estimated to be worth $25bn and will grow at a CAGR of 5.4% through 2027.
  • The study suggests that selected PhotosoftTM compounds are more effective and safer against the virus than the control (benchmark) antibiotic Monensin.
  • This is the first set of test results on infectious diseases, and it comes at a time when the world is on heighten alert to the next pandemic.

Invion Limited (ASX: IVX) has set its first foot forward in the multi-billion Zika virus market with excellent preliminary results from in vitro studies of the PhotosoftTM technology. The study results highlighted that selected PhotosoftTM compounds are effective against the virus and more efficacious than Monensin.

This is the first set of studies using PhotosoftTM compounds on infectious diseases. The development presents potential for the technology in a period where the next global pandemic could be waiting around the corner, said IVX Chairman and CEO Thian Chew.  

PhotosoftTM is a novel next-generation Photodynamic Therapy (PDT) currently under development by Invion.  

IVX tapping the multi-billion-dollar industry

Zika has been reported in 86 countries, particularly in Asia and Africa. Currently, no treatment is available for Zika virus infection or its associated diseases. The estimated market size of the Zika virus is worth US$16.98 billion (AU$25 billion) in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 5.4% to 2027, as per the company update referring to a report by Market Data Forecast.

Further, a recent report titled “Strengthening Australia’s Pandemic Preparedness” by CSIRO highlighted the development of novel antivirals as a major area of science and technology for bolstering the pandemic preparedness of the country.

Symptoms of the Zika virus, mainly transmitted by the Aedes Aegypti mosquito, include headache, joint pain, and skin rash. The virus has been linked to birth defects and other neurological complications.

Summary of results from the study

The study of PhotosoftTM against the virus was conducted by Viroclinics-DDL and Virology Research Services. Viroclinics is a leading contract research and clinical laboratory service company.

The study used Zika Strain MP1751 (African lineage). The assessment was done using a quantitative assay to measure virus replication in the presence of increasing concentrations of the PhotosoftTM compounds and a control compound (Monensin) compared to replication in the absence of the product.

Monensin is known to have anti-Zika activity in in vitro tests, but its in vivo toxicity renders it unfit for use in humans.

Following are the main highlights of the results:

  • On exposure to specific light wavelengths, selected PhotosoftTM compounds exhibited more than 99% inhibition, i.e., antiviral activity against Zika
  • Cytotoxicity levels were also lower
  • PhotosoftTM compounds had more than 190 times higher therapeutic index than Monensin

Image source: IVX update

Image description: Photosoft versus Monensin

To sum up, the studies demonstrated that selected PhotosoftTM compounds are effective against the virus. They were also more efficient than the control (benchmark) antibiotic Monensin.

At the time of writing this article, share price of Invion was AU$0.013 apiece on 8 September 2022.  

   

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

Featured Articles

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK